The pathogenesis of BK polyomavirus (BKV) infection and associated nephropathy in renal transplant recipients is not clearly understood. To gain insight, urine and plasma samples were collected from 112 renal transplant recipients before and after transplantation and tested for the presence of BKV by polymerase chain reaction. Detection of BKV infection very early (ie, 5 days) after transplantation was identified as a risk factor for subsequent BKV viremia and BKV-associated nephropathy. Phylogenetic analysis of VP1 sequences with corresponding ethnicity data suggests that reactivation was of donor origin. Thus, early testing of urine samples from renal transplant recipients may identify those at risk for BKV-associated nephropathy.
Following the introduction of newer, more potent immunosuppressive agents over the past 10-15 years, BK polyomavirus (BKV)-associated nephropathy has become established as an important cause of posttransplantation renal failure. Primary infection with BKV occurs in approximately 90% of individuals and remains latent in the tubular epithelial cells of the urogenital tract [1] .
Symptomatic BKV reactivation is uncommon in immunocompetent persons. Immunosuppression of renal transplant recipients results in the activation of BKV from the donor or recipient, with progressive infection of the kidney tubular cells. BKV viruria develops from lysis of tubule cells and leakage of virus into the lumen. The risk of BKV replication is highest in the first 2-6 months after transplantation [2, 3] . Damage to the urogenital basement membrane occurs with high levels of BKV viruria, which permits vascular spread and development of BKV viremia. Prolonged BKV viremia, tubular injury, and necrosis may result in BKV-associated nephropathy, which develops in 1%-10% of renal transplant recipients [4] . Before BKV-associated nephropathy was described, this condition was probably misdiagnosed in many renal transplant recipients, who were inappropriately treated as a result (often for acute cellular rejection), leading to graft failure.
There are 4 BKV subtypes. Subtypes I and IV are geographically widespread and commonly found in renal transplant recipients and bone marrow transplant patients. Subtypes II and III occur more rarely. A study examining the comigration rates of BKV among American, European, and Asian populations, using the VP1 region of the genome, found that subtype I was prevalent throughout the world [5] .
Steroid-sparing regimens have been used in renal transplantation since 1999. Avoidance of steroids provides improvement in the risk of cardiovascular disease and bone disease. The aim of this study was to investigate the natural history of BKV infection and disease in renal transplant recipients by analyzing the prevalence and dynamics of BKV infections in a randomized controlled study of 2 steroid-sparing regimens. Analysis of demographic data was performed to determine risk factors for BKV infection and disease.
METHODS
This study was approved by the Leeds Research Ethics Committee (reference no. 06/Q1206/64). One hundred and twenty new renal transplant recipients were recruited from November 2006 to December 2009 into 2 steroid-sparing treatment groups at Leeds Teaching Hospitals NHS Trust [6] . One patient withdrew following randomization, 2 patients did not proceed to transplantation after having been randomized, and 1 patient was lost to follow-up. The control group received basiliximab antibody induction followed by tacrolimus and mycophenolate mofetil maintenance therapy. The study group received alemtuzumab induction and tacrolimus monotherapy.
No oral maintenance steroids were routinely given to either group after the operation. Urine and plasma samples were collected before transplantation, 5 days after transplantation, monthly during months 1-6 after transplantation, and 9 and 12 months after transplantation. Patients who had at least 3 months of follow up were included in this analysis. Four patients were excluded because of inadequate follow up; two patients died during the early period after transplantation, and 2 had early graft failure. Samples were tested using a quantitative real-time polymerase chain reaction (PCR) assay, and partial genome sequencing was performed on selected samples positive for BKV.
Baseline demographic data, including ethnicity, were obtained from donors and recipients. One year after transplantation, the following information was collected: creatinine levels at 3, 6, and 12 months; whether delayed graft function occurred; presence of biopsy-proven acute rejection; and patient and graft survival.
Nucleic acid was extracted from the samples, and real-time quantitative BKV PCR was performed as described previously [3] . The donor and BKV-positive recipient serostatuses were assessed before and after transplantation. Antibody testing was performed by the hemagglutination inhibition assay, using recombinant BKV VP1 virus-like particles (VLPs) as described previously [3] . To determine the BKV subtype/subgroup, partial VP1 genome nucleotide sequencing was performed on BKV-positive samples obtained early and late after transplantation. A nested conventional PCR assay was performed using first round primers (forward: CAA GTG CCA AAA CTA CTA AT; and reverse: TGC ATG AAG GTT AAG CAT GC) and a second round primer (reverse: GTT AAG CAT GCT AGT TAT TC) taken from previously published studies [7, 8] . The second round forward primer (AGA TGA AAA CCT TAG GGG CT) was redesigned, which was found to increase sensitivity from 10 6 to 10 3 copies/mL. Following extraction of sample DNA, 2 rounds of conventional PCR reactions were performed on the Veriti Thermal Cycler (Applied Biosystems Europe BV, United Kingdom). The PCR reaction master mix (MMX) contained 25 µL of Qiagen Taq PCR MMX (Qiagen, United Kingdom), 15 µL of distilled water, 2.5 µL of forward and reverse primer at 5 µM concentrations, and 5 µL of DNA extract. The thermal profile reaction conditions for both first and second round amplification of the BKV VP1 region were 95°C for 3 minutes, followed by 45 cycles of 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 45 seconds, and 72°C for 10 minutes, and then 4°C thereafter. Partial VP1 sequences were analyzed by the unweighted pair group method with arithmetic mean in BioNumerics software, version 5.10 (Applied Maths, BioSystematica, Wales, United Kingdom), and phylogenetic analysis was performed by global cluster analysis. Alignments were performed using additional reference-based sequences downloaded from GenBank. The partial VP1 region nucleotide sequence data reported in this article were submitted to GenBank (accession numbers JX311313-JX311349).
Mann-Whitney U analysis and 1-way analysis of variance was performed using IBM SPSS Statistics, version 19 for Windows (SPSS, United Kingdom). Continuous variables were analyzed using a t test in Excel 2003 (Microsoft). The χ 2 test was used to compare categorical data, and the Fisher exact test was used when the expected number of data points was <5.
RESULTS
There was no significant difference observed between patients positive and those negative for BKV with respect to recipient or donor demographic characteristics (Table 1) . Similarly, no significant differences were identified between patients who were given basiliximab (the control group) and those who received alemtuzumab (the study group) for recipient or donor with respect to demographic characteristics, creatinine levels, or patient and graft survival at 1 year (data not shown). Despite a preponderance of BKV infections in the study group, no significant difference was observed between the 2 treatment groups for cases of BKV viremia and resulting BKV-associated nephropathy (Table 1) . BKV immunoglobulin G (IgG) antibody was detected in all donor and recipient samples. Overall, 37 of 112 renal transplant recipients were positive for BKV viruria at any one time, of whom 12 developed BKV viremia, and 2 progressed to BKV-associated nephropathy. All pretransplantation samples were negative for BKV by PCR. The overall mean peak level of BKV DNA detected in urine was 6.3 × 10 9 copies/mL (range, 2.6 × 10 2 to 9.7 × 10 10 copies/mL).
For plasma, the mean peak level was 3.4 × 10 5 copies/mL (range, 3.6 × 10 2 to 3.1 × 10 6 copies/mL). The median time to detection of BKV viruria was 2 months (range, 5 days to 12 months) after transplantation; the median time to BKV viremia was 2-3 months (range, 1-6 months) after transplantation. Early detection of BKV viruria, on day 5 after transplantation (median time to detection, 5 days; range, 1-23 days), appeared to be a risk factor for subsequent viremia. Ten patients had early viruria, of whom 7 progressed to viremia. In contrast, only 5 of 27 patients with viruria occurring >5 days after transplantation progressed to viremia. Thus, early viruria was a significant predictor of viremia (P = .006, by the Fisher exact test). The sensitivity, specificity, positive predictive value, and negative predictive value of early BKV viruria as an early indicator of subsequent viremia was 58%, 88%, 81%, and 70%, respectively. The majority of patients (91%) were negative for BKV viruria 5 days after transplantation. Both cases of BKVassociated nephropathy had BKV viruria detected 5 days after transplantation and had prolonged viremia (duration, 6 and 7 months). The peak urine viral load in each patient was 4.5 × 10 10 copies/mL and 9.7 × 10 10 copies/mL, and the peak plasma viral load was 1.7 × 10 5 and 1.2 × 10 6 copies/mL.
To investigate the likely source of BKV, VP1 sequences of strains from urine and plasma samples from 36 patients early and late after transplantation were amplified and sequenced. Of the 12 renal transplant recipients positive for BKV viremia, 8 had plasma samples with sufficiently high viral loads (>10 3 copies/mL) to allow amplification and sequence determination.
The alignment of VP1 sequences identified 4 predominant groups (Ia, Ib-1, Ib-2, and II) (Figure 1 ). Only 1 patient (patient 44) had 2 different subgroups identified. This patient had a subgroup Ib-1 strain in urine 6 months after transplantation and a subgroup Ia strain in urine 12 months after transplantation. The alignment identified 2 outlier patients. Patient 3 had a subgroup Ib-2 strain, which was distinct from the other Ib-2 strains. Patient 85 was infected with a subtype IV strain. In cases where BKV reactivation was detected in both urine and plasma, both isolates were identical. Five recipient/donor ethnicity mismatches were identified, all of which involved white donors, and strains from 4 of these aligned within one of the predominant groups.
DISCUSSION
In the present study, no significant risk factor was identified for BKV infection. The majority (>90%) of renal transplant recipients were white, and there was a higher proportion of males compared with females (ratio, 3:1). The mean age was 48 years. It is perhaps therefore not surprising that the 2 BKV-associated nephropathy cases matched this profile, which is common to other studies [9, 10] . Abbreviations: BPAR, biopsy-proven acute rejection; CMV, cytomegalovirus; RTR, renal transplant recipient; -, negative; +, positive.
The prevalence of BKV DNA in urine was 33%. One-third of these patients progressed to BKV viremia, and 2 patients developed BKV-associated nephropathy. This prevalence of BKV viruria is similar to that in other published studies, which reported a range of 27% to 46% [3, 11] . The prevalence for BKV viremia was 10.7% in the current study. This is at the low end of the range from other studies, which reported prevalences of 7.5%-28% [12, 13] . No patients lost their graft because of BKV-associated nephropathy.
BKV viruria was observed in the sample obtained early after transplantation in 27% of the positive cases, and it was a significant risk factor for subsequent development of viremia and was observed in both cases of BKV-associated nephropathy. This finding has not been reported previously. Larger studies are required to confirm early infection as a necessary step to subsequent development of BKV-associated nephropathy and to determine the optimum time to test after transplantation. Our results also support previous studies that suggested that sustained viruria (≥1 × 10 9 copies/mL) and viremia (≥1 × 10 5 copies/mL) are predictors of BKV-associated nephropathy.
Because all donors and recipients were BKV-antibody positive in this study, serostatus could not be used to indicate the source of BKV. However, BKV subtypes and subgroups have distinct geographical distributions, and this was used along with ethnicity as a proxy of strain origin. BKV subtype I was the most prevalent strain identified. Four common referencebased groups were detected: Ib-1 (35%), Ib-2 (27%), Ia (19%), and II (13.5%) [14] . Only 1 patient had a change in predominant BKV subgroup, which may represent a switch from a donor to a recipient strain. No renal transplant recipients had mixed BKV infection, although population-based sequencing (which has a low sensitivity for the detection of mixed infections) was used. Of interest, patient 3 had a BKV subgroup Ib-2 virus that was distinct from BKV strains recovered from other patients with this subgroup. This strain most closely resembles a previous report of a Finnish virus (GenBank accession no. AB263918). One renal transplant recipient ( patient 85) was identified with BKV subtype IV, which has previously rarely been identified from renal transplant recipients in Europe and Asia [14] . Alignments were performed using additional reference-based sequences downloaded from GenBank [14] . The alignment identified 4 predominant groups (Ia, Ib-1, Ib-2, and II) and 2 outliers (from patients 3 and 85). The sequence from patient 44 was identified as both subgroup Ib-1 and Ia by nucleotide analysis of urine and plasma. The majority of renal transplant recipients were white with white donors, except the following patients (denoted by asterisks): patients 3 and 67 (Asian), patients 108 and 112 (black), and patient 98 (another ethnicity). GenBank accession numbers are as follows: BKV THK-8, AB211390; BK RYU-3, AB211389; BK HC-u9, AY628236; BK HC-u5, AY628235; BK GBR-9, AB263924; BK FNL-12, AB263918; BK KOM-5, AB211374; BK COMPLETE GENOME, NC_001538; BK DUNLOP, V01108; BK KOM-6, AB211375; BK SB, Z19536; and BK AS, M23122.
Ethnicity mismatch between donor and recipient was found for 5 cases. All these recipients were of a race/ethnicity other than white and had white donors. Four of these strains aligned with common reference-based subgroups Ib-1 and Ib-2 observed in this study. The fifth strain aligned with subtype II, an uncommon subtype but previously identified in Europe. These data support at least 1 other report, providing evidence that BKV infection is of donor origin [15] .
In conclusion, this study suggests that early reactivation of BKV in the donor kidney is an important initial step in the development of BKV-associated nephropathy. However, other factors are necessary for disease progression, because only a small proportion of patients who progress to high-level viruria and viremia subsequently develop BKV-associated nephropathy.
